{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:55:32Z","timestamp":1787961332164,"version":"build-2784847793"},"reference-count":126,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Renal and urinary tract complications related to inflammatory bowel disease (IBD) have been relatively understudied in the literature compared with other extraintestinal manifestations. Presentation of these renal manifestations can be subtle, and their detection is complicated by a lack of clarity regarding the optimal screening and routine monitoring of renal function in IBD patients. Urolithiasis is the most common manifestation. Penetrating Crohn\u2019s disease involving the genitourinary system as an extraintestinal complication is rare but associated with considerable morbidity. Some biologic agents used to treat IBD have been implicated in progressive renal impairment, although differentiating between drug-related side effects and deteriorating kidney function due to extraintestinal manifestations can be challenging. The most common findings on renal biopsy of IBD patients with renal injury are tubulointerstitial nephritis and IgA nephropathy, the former also being associated with drug-induced nephrotoxicity related to IBD medication. Amyloidosis, albeit rare, must be diagnosed early to reduce the chance of progression to renal failure. In this review, we evaluate the key literature relating to renal and urological involvement in IBD and emphasize the high index of suspicion required for the prompt diagnosis and treatment of these manifestations and complications, considering the potential severity and implications of acute or chronic loss of renal function. We also provide suggestions for future research priorities.<\/jats:p>","DOI":"10.1093\/ibd\/izac140","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T07:29:15Z","timestamp":1660030155000},"page":"1306-1316","source":"Crossref","is-referenced-by-count":46,"title":["Renal and Urological Disorders Associated With Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-8791","authenticated-orcid":false,"given":"Shankar","family":"Kumar","sequence":"first","affiliation":[{"name":"Centre for Medical Imaging, University College London , 2nd Floor Charles Bell House, 43\u201345 Foley Street, W1W 7TS, London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pollok","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospitals NHS Foundation Trust , Blackshaw Road, London, SW17 0QT , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldsmith","sequence":"additional","affiliation":[{"name":"Renal and Transplantation Department, Guys and St Thomas\u2019 Hospitals NHS Foundation Trust, Great Maze Pond , London SE1 9RT , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"issue":"4","key":"2023080117201383800_CIT0001","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology."},{"issue":"30","key":"2023080117201383800_CIT0002","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.3748\/wjg.v12.i30.4819","article-title":"Extraintestinal manifestations and complications in inflammatory bowel diseases","volume":"12","author":"Rothfuss","year":"2006","journal-title":"World J Gastroenterol."},{"issue":"5","key":"2023080117201383800_CIT0003","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","article-title":"The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy","volume":"13","author":"Hedin","year":"2019","journal-title":"J Crohns Colitis."},{"issue":"6","key":"2023080117201383800_CIT0004","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0022-5347(17)59341-6","article-title":"Urologic complications of inflammatory bowel disease","volume":"115","author":"Shield","year":"1976","journal-title":"J Urol."},{"issue":"5","key":"2023080117201383800_CIT0005","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005792-197609000-00004","article-title":"The extra-intestinal complications of Crohn\u2019s disease and ulcerative colitis: a study of 700 patients","volume":"55","author":"Greenstein","year":"1976","journal-title":"Medicine (Baltim)."},{"issue":"1","key":"2023080117201383800_CIT0006","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12882-021-02358-2","article-title":"Different renal manifestations associated with very early onset pediatric inflammatory bowel disease: case report and review of literature","volume":"22","author":"Angeletti","year":"2021","journal-title":"BMC Nephrol."},{"issue":"Suppl 3","key":"2023080117201383800_CIT0007","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut."},{"issue":"2","key":"2023080117201383800_CIT0008","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/00365528708991889","article-title":"Cholelithiasis and urolithiasis in Crohn\u2019s disease","volume":"22","author":"Andersson","year":"1987","journal-title":"Scand J Gastroenterol."},{"issue":"11","key":"2023080117201383800_CIT0009","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1136\/gut.33.11.1493","article-title":"Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones, but does not change high prevalence of gall stones in patients with a short bowel","volume":"33","author":"Nightingale","year":"1992","journal-title":"Gut."},{"issue":"9","key":"2023080117201383800_CIT0010","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1046\/j.1464-410X.2002.02739.x","article-title":"Risk factors for developing renal stones in inflammatory bowel disease","volume":"89","author":"McConnell","year":"2002","journal-title":"BJU Int."},{"issue":"1","key":"2023080117201383800_CIT0011","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eururo.2012.03.052","article-title":"Prevalence of kidney stones in the United States","volume":"62","author":"Scales","year":"2012","journal-title":"Eur Urol."},{"key":"2023080117201383800_CIT0012","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/IJNRD.S45466","article-title":"Nephrolithiasis in patients with inflammatory bowel disease in the community","volume":"6","author":"Cury","year":"2013","journal-title":"Int J Nephrol Renovasc Dis."},{"issue":"10","key":"2023080117201383800_CIT0013","doi-asserted-by":"crossref","first-page":"e0185193","DOI":"10.1371\/journal.pone.0185193","article-title":"Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases","volume":"12","author":"Fagagnini","year":"2017","journal-title":"PLoS One."},{"issue":"1","key":"2023080117201383800_CIT0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12894-021-00951-z","article-title":"Urinary manifestations in African American and Caucasian inflammatory bowel disease patients: a retrospective cohort study","volume":"22","author":"Herbert","year":"2022","journal-title":"BMC Urol."},{"issue":"2","key":"2023080117201383800_CIT0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pop.2019.02.008","article-title":"Hematuria","volume":"46","author":"Peterson","year":"2019","journal-title":"Prim Care."},{"issue":"4","key":"2023080117201383800_CIT0016","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0889-8529(02)00035-X","article-title":"Stones from bowel disease","volume":"31","author":"Worcester","year":"2002","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"2","key":"2023080117201383800_CIT0017","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11255-020-02649-x","article-title":"Urolithiasis in complicated inflammatory bowel disease: a comprehensive analysis of urine profile and stone composition","volume":"53","author":"Torricelli","year":"2021","journal-title":"Int Urol Nephrol."},{"issue":"7453","key":"2023080117201383800_CIT0018","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/bmj.328.7453.1420","article-title":"Kidney stones","volume":"328","author":"Parmar","year":"2004","journal-title":"BMJ."},{"issue":"3","key":"2023080117201383800_CIT0019","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/ndt\/gfv005","article-title":"Enteric hyperoxaluria: an important cause of end-stage kidney disease","volume":"31","author":"Nazzal","year":"2016","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"2023080117201383800_CIT0020","first-page":"89","article-title":"Low-oxalate, low-fat dietary regimen in hyperoxaluria following jejunoileal bypass","volume":"149","author":"Nordenvall","year":"1983","journal-title":"Acta Chir Scand."},{"issue":"4","key":"2023080117201383800_CIT0021","doi-asserted-by":"crossref","first-page":"143","DOI":"10.5527\/wjn.v3.i4.143","article-title":"Why do young people with chronic kidney disease die early","volume":"3","author":"Kumar","year":"2014","journal-title":"World J Nephrol."},{"issue":"1","key":"2023080117201383800_CIT0022","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1523-1755.2003.00725.x","article-title":"Urine stone risk factors in nephrolithiasis patients with and without bowel disease","volume":"63","author":"Parks","year":"2003","journal-title":"Kidney Int."},{"issue":"5872","key":"2023080117201383800_CIT0023","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/bmj.3.5872.141","article-title":"Blood and urinary changes in patients with ileostomies and ileorectal anastomoses","volume":"3","author":"Singer","year":"1973","journal-title":"Br Med J."},{"issue":"3","key":"2023080117201383800_CIT0024","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7762\/cnr.2015.4.3.137","article-title":"Nutritional Management of Kidney Stones (Nephrolithiasis)","volume":"4","author":"Han","year":"2015","journal-title":"Clin Nutr Res."},{"issue":"4","key":"2023080117201383800_CIT0025","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.urology.2014.12.011","article-title":"Urolithiasis and urinary tract infection among patients with inflammatory bowel disease: a review of US emergency department visits between 2006 and 2009","volume":"85","author":"Varda","year":"2015","journal-title":"Urology."},{"issue":"3","key":"2023080117201383800_CIT0026","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.eururo.2015.07.040","article-title":"EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis","volume":"69","author":"Turk","year":"2016","journal-title":"Eur Urol."},{"issue":"2","key":"2023080117201383800_CIT0027","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2214\/AJR.07.3414","article-title":"Diagnostic performance of low-dose CT for the detection of urolithiasis: a meta-analysis","volume":"191","author":"Niemann","year":"2008","journal-title":"AJR Am J Roentgenol."},{"issue":"2","key":"2023080117201383800_CIT0028","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/end.2019.0574","article-title":"Ultra-low-dose CT: an effective follow-up imaging modality for ureterolithiasis","volume":"34","author":"Cheng","year":"2020","journal-title":"J Endourol."},{"issue":"8","key":"2023080117201383800_CIT0029","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.crad.2019.03.013","article-title":"Diagnostic pathways in Crohn\u2019s disease","volume":"74","author":"Rao","year":"2019","journal-title":"Clin Radiol."},{"issue":"2","key":"2023080117201383800_CIT0030","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00054725-200203000-00007","article-title":"Management of internal fistulas in Crohn\u2019s disease","volume":"8","author":"Levy","year":"2002","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"2023080117201383800_CIT0031","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/ecco-jcc\/jjw016","article-title":"Outcomes of medical and surgical therapy for entero-urinary fistulas in Crohn\u2019s disease","volume":"10","author":"Taxonera","year":"2016","journal-title":"J Crohns Colitis."},{"issue":"10","key":"2023080117201383800_CIT0032","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/apt.16326","article-title":"Review article: investigation and management of internal fistulae in Crohn\u2019s disease","volume":"53","author":"Tjandra","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2023080117201383800_CIT0033","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4240\/wjgs.v12.i5.208","article-title":"When the bowel meets the bladder: optimal management of colorectal pathology with urological involvement","volume":"12","author":"Keady","year":"2020","journal-title":"World J Gastrointest Surg."},{"issue":"8","key":"2023080117201383800_CIT0034","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1177\/000313480206800811","article-title":"Diagnosis and management of enterovesical fistulas in patients with Crohn\u2019s disease","volume":"68","author":"Gruner","year":"2002","journal-title":"Am Surg."},{"issue":"6","key":"2023080117201383800_CIT0035","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1046\/j.1463-1318.2002.00370.x","article-title":"Diagnostic lessons learnt from a series of enterovesical fistulae","volume":"4","author":"Daniels","year":"2002","journal-title":"Colorectal Dis."},{"key":"2023080117201383800_CIT0036","doi-asserted-by":"crossref","first-page":"617967","DOI":"10.1155\/2013\/617967","article-title":"Enterovesical fistulae: aetiology, imaging, and management","volume":"2013","author":"Golabek","year":"2013","journal-title":"Gastroenterol Res Pract."},{"key":"2023080117201383800_CIT0037","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjac062","article-title":"Diagnostic performance of magnetic resonance enterography disease activity indices compared with a histological reference standard for adult terminal ileal Crohn\u2019s disease: experience from the METRIC trial","author":"Kumar","year":"2022","journal-title":"Journal of Crohn\u2019s and Colitis."},{"issue":"7","key":"2023080117201383800_CIT0038","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1572-0241.2003.07521.x","article-title":"Contrast radiology, computed tomography and ultrasonography in detecting internal fistulas and intra-abdominal abscesses in Crohn\u2019s disease: a prospective comparative study","volume":"98","author":"Maconi","year":"2003","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"2023080117201383800_CIT0039","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/jgh.12724","article-title":"Small intestinal contrast ultrasonography for the detection of small bowel complications in Crohn\u2019s disease: correlation with intraoperative findings and magnetic resonance enterography","volume":"30","author":"Kumar","year":"2015","journal-title":"J Gastroenterol Hepatol."},{"issue":"2","key":"2023080117201383800_CIT0040","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/jgh3.12228","article-title":"Comparison of small intestinal contrast ultrasound with magnetic resonance enterography in pediatric Crohn\u2019s disease","volume":"4","author":"Hakim","year":"2020","journal-title":"JGH Open."},{"issue":"1","key":"2023080117201383800_CIT0041","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ibd.21678","article-title":"Small intestine contrast ultrasonography (SICUS) for the detection of small bowel complications in crohn\u2019s disease: a prospective comparative study versus intraoperative findings","volume":"18","author":"Pallotta","year":"2012","journal-title":"Inflamm Bowel Dis."},{"issue":"1018","key":"2023080117201383800_CIT0042","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1259\/bjr\/55871151","article-title":"Imaging features of colovesical fistulae on MRI","volume":"85","author":"Tang","year":"2012","journal-title":"Br J Radiol."},{"issue":"48","key":"2023080117201383800_CIT0043","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.3748\/wjg.v19.i48.9359","article-title":"Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease","volume":"19","author":"Algaba","year":"2013","journal-title":"World J Gastroenterol."},{"issue":"9701","key":"2023080117201383800_CIT0044","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet."},{"issue":"7","key":"2023080117201383800_CIT0045","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/ajg.2009.760","article-title":"Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies","volume":"105","author":"Pedersen","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"2023080117201383800_CIT0046","doi-asserted-by":"crossref","first-page":"636791","DOI":"10.3389\/fsurg.2021.636791","article-title":"Risk of urinary bladder cancer in patients with inflammatory bowel diseases: a meta-analysis","volume":"8","author":"Geng","year":"2021","journal-title":"Front Surg."},{"issue":"Suppl 1","key":"2023080117201383800_CIT0047","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000509544","article-title":"malignancies in inflammatory bowel disease","volume":"101","author":"Greuter","year":"2020","journal-title":"Digestion."},{"key":"2023080117201383800_CIT0048","doi-asserted-by":"crossref","first-page":"788980","DOI":"10.3389\/fonc.2021.788980","article-title":"The incidence rate and risk factors of malignancy in elderly-onset inflammatory bowel disease: a Chinese cohort study from 1998 to 2020","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol."},{"key":"2023080117201383800_CIT0049","first-page":"CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn\u2019s disease","volume":"7","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"issue":"10","key":"2023080117201383800_CIT0050","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1365-2036.2005.02462.x","article-title":"Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom","volume":"21","author":"Muller","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"2023080117201383800_CIT0051","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/ecco-jcc\/jjv219","article-title":"Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease","volume":"10","author":"Heap","year":"2016","journal-title":"J Crohns Colitis."},{"issue":"3","key":"2023080117201383800_CIT0052","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1155\/2009\/501345","article-title":"Renal effects of long-term treatment with 5-aminosalicylic acid","volume":"23","author":"Patel","year":"2009","journal-title":"Can J Gastroenterol."},{"issue":"7","key":"2023080117201383800_CIT0053","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1053\/j.gastro.2004.03.016","article-title":"5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study","volume":"126","author":"Van Staa","year":"2004","journal-title":"Gastroenterology."},{"issue":"4","key":"2023080117201383800_CIT0054","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/apt.15408","article-title":"No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study","volume":"50","author":"Jairath","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"2023080117201383800_CIT0055","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/j.gastro.2018.12.009","article-title":"AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis","volume":"156","author":"Ko","year":"2019","journal-title":"Gastroenterology."},{"issue":"3","key":"2023080117201383800_CIT0056","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/jgh.15185","article-title":"Asian Organization for Crohn\u2019s and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia","volume":"36","author":"Ran","year":"2021","journal-title":"J Gastroenterol Hepatol."},{"issue":"3","key":"2023080117201383800_CIT0057","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Practice parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"2023080117201383800_CIT0058","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.crohns.2007.11.002","article-title":"European evidence-based consensus on the management of ulcerative colitis: current management","volume":"2","author":"Travis","year":"2008","journal-title":"J Crohns Colitis."},{"issue":"2","key":"2023080117201383800_CIT0059","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"issue":"9","key":"2023080117201383800_CIT0060","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/apt.15687","article-title":"Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease","volume":"51","author":"Rodriguez-Lago","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2023080117201383800_CIT0061","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/ibd\/izz068","article-title":"Tacrolimus therapy in steroid-refractory ulcerative colitis: a review","volume":"26","author":"Wu","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"13","key":"2023080117201383800_CIT0062","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3748\/wjg.v25.i13.1603","article-title":"Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis","volume":"25","author":"Hoffmann","year":"2019","journal-title":"World J Gastroenterol."},{"issue":"26","key":"2023080117201383800_CIT0063","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med."},{"issue":"4","key":"2023080117201383800_CIT0064","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1744-9987.2006.00389.x","article-title":"Therapeutic strategies for secondary hyperparathyroidism in dialysis patients","volume":"10","author":"Ogata","year":"2006","journal-title":"Ther Apher Dial."},{"issue":"2","key":"2023080117201383800_CIT0065","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0016-5085(03)00877-1","article-title":"Tacrolimus for the treatment of fistulas in patients with Crohn\u2019s disease: a randomized, placebo-controlled trial","volume":"125","author":"Sandborn","year":"2003","journal-title":"Gastroenterology."},{"issue":"10","key":"2023080117201383800_CIT0066","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1046\/j.1365-2036.2003.01534.x","article-title":"Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease","volume":"17","author":"Baumgart","year":"2003","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"2023080117201383800_CIT0067","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/gut.2005.081794","article-title":"A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis","volume":"55","author":"Ogata","year":"2006","journal-title":"Gut."},{"issue":"12","key":"2023080117201383800_CIT0068","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124347","article-title":"CYP3A5 genotype as a potential pharmacodynamic biomarker for tacrolimus therapy in ulcerative colitis in Japanese patients","volume":"21","author":"Yamamoto","year":"2020","journal-title":"Int J Mol Sci."},{"issue":"4","key":"2023080117201383800_CIT0069","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0016-5085(03)01214-9","article-title":"Randomized, double-blind comparison of 4 mg\/kg versus 2 mg\/kg intravenous cyclosporine in severe ulcerative colitis","volume":"125","author":"Van Assche","year":"2003","journal-title":"Gastroenterology."},{"issue":"2","key":"2023080117201383800_CIT0070","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/ecco-jcc\/jjv138","article-title":"Renal involvement in inflammatory bowel diseases","volume":"10","author":"Corica","year":"2016","journal-title":"J Crohns Colitis."},{"issue":"9","key":"2023080117201383800_CIT0071","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1002\/jcb.25140","article-title":"The protective effect of apocynin on cyclosporine a-induced hypertension and nephrotoxicity in rats","volume":"116","author":"Ciarcia","year":"2015","journal-title":"J Cell Biochem."},{"issue":"5","key":"2023080117201383800_CIT0072","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0270-9295(03)00090-1","article-title":"Cyclosporine nephrotoxicity","volume":"23","author":"Burdmann","year":"2003","journal-title":"Semin Nephrol."},{"key":"2023080117201383800_CIT0073","doi-asserted-by":"crossref","first-page":"815117","DOI":"10.3389\/fphar.2021.815117","article-title":"Editorial: therapeutic drug monitoring in solid organ transplantation","volume":"12","author":"Staatz","year":"2021","journal-title":"Front Pharmacol."},{"issue":"Suppl 1","key":"2023080117201383800_CIT0074","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000506898","article-title":"TNF-Alpha blockers in inflammatory bowel diseases: practical recommendations and a user\u2019s guide: an update","volume":"101","author":"Vulliemoz","year":"2020","journal-title":"Digestion."},{"issue":"1","key":"2023080117201383800_CIT0075","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s12882-020-02015-0","article-title":"IgA nephropathy in a patient receiving infliximab for generalized pustular psoriasis","volume":"21","author":"Segawa","year":"2020","journal-title":"BMC Nephrol."},{"issue":"2","key":"2023080117201383800_CIT0076","doi-asserted-by":"crossref","first-page":"249","DOI":"10.15403\/jgld.2014.1121.242.infx","article-title":"Nephrotic syndrome after infliximab treatment in a patient with ulcerative colitis","volume":"24","author":"Dumitrescu","year":"2015","journal-title":"J Gastrointestin Liver Dis."},{"issue":"3","key":"2023080117201383800_CIT0077","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00296-019-04241-8","article-title":"Infliximab-associated focal segmental glomerulosclerosis in a patient with ankylosing spondylitis","volume":"39","author":"Yarkan Tugsal","year":"2019","journal-title":"Rheumatol Int"},{"issue":"1","key":"2023080117201383800_CIT0078","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.ajkd.2017.08.008","article-title":"Interstitial nephritis secondary to vedolizumab treatment in Crohn disease and safe rechallenge using steroids: a case report","volume":"71","author":"Bailly","year":"2018","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"2023080117201383800_CIT0079","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.nefroe.2018.06.016","article-title":"Nephrotic syndrome in relation to treatment with ustekinumab","volume":"39","author":"Perez Fernandez","year":"2019","journal-title":"Nefrologia (Engl Ed)"},{"key":"2023080117201383800_CIT0080","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izab357","article-title":"Long-term real-world effectiveness and safety of ustekinumab in Crohn\u2019s disease patients: the SUSTAIN study","author":"Chaparro","year":"2022","journal-title":"Inflamm Bowel Dis."},{"key":"2023080117201383800_CIT0081","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13075-015-0612-7","article-title":"Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial","volume":"17","author":"Kremer","year":"2015","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"2023080117201383800_CIT0082","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/jcph.1375","article-title":"Characterization of the effect of renal impairment on upadacitinib pharmacokinetics","volume":"59","author":"Mohamed","year":"2019","journal-title":"J Clin Pharmacol."},{"key":"2023080117201383800_CIT0083","article-title":"Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis","author":"D\u2019Amico","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"10","key":"2023080117201383800_CIT0084","first-page":"706","article-title":"Gebbers JO. Hypocomplementemic membranoproliferative glomerulonephritis in a child with ulcerative colitis (author\u2019s transl)","volume":"124","author":"Hellwege","year":"1976","journal-title":"Monatsschr Kinderheilkd."},{"issue":"17","key":"2023080117201383800_CIT0085","first-page":"1083","article-title":"Meyrier A. Immunoglobulin A glomerular nephropathy associated with inflammatory colitis. Apropos of 2 cases","volume":"13","author":"Hubert","year":"1984","journal-title":"Presse Med."},{"issue":"10","key":"2023080117201383800_CIT0086","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00467-002-0943-x","article-title":"An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications","volume":"17","author":"Takemura","year":"2002","journal-title":"Pediatr Nephrol."},{"issue":"5","key":"2023080117201383800_CIT0087","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00384-004-0696-z","article-title":"IgA nephropathy in association with Crohn\u2019s disease","volume":"20","author":"Forshaw","year":"2005","journal-title":"Int J Colorectal Dis."},{"issue":"9","key":"2023080117201383800_CIT0088","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00467-005-1986-6","article-title":"Membranous nephropathy associated with familial chronic ulcerative colitis in a 12-year-old girl","volume":"20","author":"Ridder","year":"2005","journal-title":"Pediatr Nephrol."},{"issue":"8","key":"2023080117201383800_CIT0089","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/ard.49.8.638","article-title":"Inflammatory bowel disease and ankylosing spondylitis associated with cutaneous vasculitis, glomerulonephritis, and circulating IgA immune complexes","volume":"49","author":"Peeters","year":"1990","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"2023080117201383800_CIT0090","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3109\/08860221003710554","article-title":"IgA nephropathy in association with Crohn\u2019s disease: a case report and brief review of the literature","volume":"32","author":"Filiopoulos","year":"2010","journal-title":"Ren Fail."},{"issue":"2","key":"2023080117201383800_CIT0091","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5414\/CN106770","article-title":"IgA nephropathy in a patient with ulcerative colitis, Graves\u2019 disease and positive myeloperoxidase ANCA","volume":"77","author":"Ku","year":"2012","journal-title":"Clin Nephrol."},{"issue":"2","key":"2023080117201383800_CIT0092","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2215\/CJN.04660513","article-title":"The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease","volume":"9","author":"Ambruzs","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"2023080117201383800_CIT0093","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ckj\/sfz004","article-title":"Inflammatory bowel disease in patients undergoing renal biopsies","volume":"12","author":"Pohjonen","year":"2019","journal-title":"Clin Kidney J."},{"issue":"3","key":"2023080117201383800_CIT0094","first-page":"381","article-title":"Patterns of renal involvement in a cohort of patients with inflammatory bowel disease in Egypt","volume":"81","author":"Elaziz","year":"2018","journal-title":"Acta Gastroenterol Belg."},{"issue":"2","key":"2023080117201383800_CIT0095","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10620-006-3144-9","article-title":"Concomitant aseptic subcutaneous abscess and immunoglobulin m nephropathy--rare extraintestinal manifestations in ulcerative colitis","volume":"51","author":"Li","year":"2006","journal-title":"Dig Dis Sci."},{"issue":"2","key":"2023080117201383800_CIT0096","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5414\/CNP60146","article-title":"Mesangiocapillary glomerulonephritis associated with ulcerative colitis: a 6-year follow-up of 2 cases","volume":"60","author":"Ashman","year":"2003","journal-title":"Clin Nephrol."},{"issue":"3","key":"2023080117201383800_CIT0097","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/ajkd.2002.34929","article-title":"Anti-glomerular basement membrane nephritis and bullous pemphigoid caused by distinct anti-alpha 3(IV)NC1 and anti-BP180 antibodies in a patient with Crohn\u2019s disease","volume":"40","author":"Plaisier","year":"2002","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"2023080117201383800_CIT0098","doi-asserted-by":"crossref","first-page":"652","DOI":"10.4161\/19490976.2014.969977","article-title":"Re-thinking the functions of IgA(+) plasma cells","volume":"5","author":"Gommerman","year":"2014","journal-title":"Gut Microbes"},{"issue":"25","key":"2023080117201383800_CIT0099","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med."},{"issue":"3","key":"2023080117201383800_CIT0100","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ibd.21793","article-title":"Host-microbe relationships in inflammatory bowel disease detected by bacterial and metaproteomic analysis of the mucosal-luminal interface","volume":"18","author":"Presley","year":"2012","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2023080117201383800_CIT0101","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000187509","article-title":"The pathogenic role of immunoglobulin A polymers in immunoglobulin A nephropathy","volume":"65","author":"Harper","year":"1993","journal-title":"Nephron."},{"issue":"5","key":"2023080117201383800_CIT0102","first-page":"230","article-title":"Circulating immune complexes containing IgA, IgG and IgM in patients with primary IgA nephropathy and with Henoch-Schoenlein nephritis. Correlation with clinical and histologic signs of activity","volume":"18","author":"Coppo","year":"1982","journal-title":"Clin Nephrol."},{"key":"2023080117201383800_CIT0103","article-title":"IgA nephropathy in association with inflammatory bowel diseases: results from a national study and systematic literature review","author":"Joher","year":"2021","journal-title":"Nephrol Dial Transplant."},{"issue":"18","key":"2023080117201383800_CIT0104","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJM198610303151819","article-title":"Dietary gluten and primary IgA nephropathy","volume":"315","author":"Coppo","year":"1986","journal-title":"N Engl J Med."},{"issue":"4","key":"2023080117201383800_CIT0105","first-page":"499","article-title":"Gluten-induced experimental IgA glomerulopathy","volume":"60","author":"Coppo","year":"1989","journal-title":"Laboratory investigation; a journal of technical methods and pathology."},{"issue":"11","key":"2023080117201383800_CIT0106","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat Genet."},{"issue":"5","key":"2023080117201383800_CIT0107","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.semnephrol.2018.05.020","article-title":"The gut-renal connection in IgA nephropathy","volume":"38","author":"Coppo","year":"2018","journal-title":"Semin Nephrol."},{"issue":"10084","key":"2023080117201383800_CIT0108","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstrom","year":"2017","journal-title":"Lancet."},{"issue":"5","key":"2023080117201383800_CIT0109","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","article-title":"Tang SCW","volume":"43","author":"Floege","year":"2021","journal-title":"Semin Immunopathol."},{"issue":"10","key":"2023080117201383800_CIT0110","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.ekir.2020.08.009","article-title":"Why target the gut to treat IgA nephropathy","volume":"5","author":"Barratt","year":"2020","journal-title":"Kidney Int Rep."},{"issue":"1","key":"2023080117201383800_CIT0111","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-021-00284-z","article-title":"Acute kidney injury","volume":"7","author":"Kellum","year":"2021","journal-title":"Nat Rev Dis Primers."},{"issue":"3","key":"2023080117201383800_CIT0112","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MNH.0b013e3283521cfa","article-title":"Renal interstitial fibrosis: mechanisms and evaluation","volume":"21","author":"Farris","year":"2012","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"3","key":"2023080117201383800_CIT0113","first-page":"127","article-title":"Drug nephrotoxicity","volume":"14","author":"Izzedine","year":"2018","journal-title":"Nephrologie & therapeutique."},{"issue":"5","key":"2023080117201383800_CIT0114","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ibd.20099","article-title":"Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review","volume":"13","author":"Gisbert","year":"2007","journal-title":"Inflamm Bowel Dis."},{"key":"2023080117201383800_CIT0115","first-page":"4260365","article-title":"Interstitialsnephritis in a patient with inflammatory bowel disease","volume":"2016","author":"Vasanth","year":"2016","journal-title":"Case Rep Nephrol."},{"issue":"3","key":"2023080117201383800_CIT0116","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2036.2001.00940.x","article-title":"Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use","volume":"15","author":"Herrlinger","year":"2001","journal-title":"Aliment Pharmacol Ther."},{"issue":"8","key":"2023080117201383800_CIT0117","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1046\/j.1365-2036.2001.01041.x","article-title":"Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy","volume":"15","author":"Fraser","year":"2001","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"2023080117201383800_CIT0118","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/MPG.0b013e31806dc2c4","article-title":"Tubulointerstitial nephritis: an extraintestinal manifestation of Crohn disease in children","volume":"46","author":"Marcus","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"3","key":"2023080117201383800_CIT0119","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1515\/CCLM.2006.050","article-title":"Urinary cystatin C as a specific marker of tubular dysfunction","volume":"44","author":"Conti","year":"2006","journal-title":"Clin Chem Lab Med."},{"issue":"12","key":"2023080117201383800_CIT0120","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/ncpneph0955","article-title":"Tubulointerstitial nephritis as an extraintestinal manifestation of Crohn\u2019s disease","volume":"4","author":"Waters","year":"2008","journal-title":"Nat Clin Pract Nephrol."},{"issue":"1","key":"2023080117201383800_CIT0121","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5858\/arpa.2012-0224-CR","article-title":"Granulomatous interstitial nephritis as a manifestation of Crohn disease","volume":"138","author":"Colvin","year":"2014","journal-title":"Arch Pathol Lab Med."},{"issue":"4","key":"2023080117201383800_CIT0122","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/ckj\/sfw041","article-title":"Granulomatous interstitial nephritis and Crohn\u2019s disease","volume":"9","author":"Timmermans","year":"2016","journal-title":"Clin Kidney J."},{"key":"2023080117201383800_CIT0123","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.14309\/crj.2017.24","article-title":"Tubulointerstitial nephritis as the initial presentation of Crohn\u2019s disease and successful treatment with infliximab","volume":"4","author":"Stanton","year":"2017","journal-title":"ACG Case Rep J."},{"issue":"10","key":"2023080117201383800_CIT0124","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/ecco-jcc\/jjw080","article-title":"Amyloidosis in inflammatory bowel disease: a systematic review of epidemiology, clinical features, and treatment","volume":"10","author":"Tosca Cuquerella","year":"2016","journal-title":"J Crohns Colitis."},{"issue":"5","key":"2023080117201383800_CIT0125","first-page":"504","article-title":"Secondary systemic amyloidosis in inflammatory bowel disease: a nationwide analysis","volume":"30","author":"Sharma","year":"2017","journal-title":"Ann Gastroenterol."},{"key":"2023080117201383800_CIT0126","volume-title":"National Institute for Health and Care Excellence guideline","author":"Chronic kidney disease: assessment and management"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izac140\/45292383\/izac140.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/8\/1306\/51017519\/izac140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/8\/1306\/51017519\/izac140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T12:13:20Z","timestamp":1700914400000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/29\/8\/1306\/6658535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":126,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,9]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izac140","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2022,8,9]]}}}